2022 World Conference on Lung Cancer (ePosters)-EP08.01-005. A Multicenter Prospective Observational Study of Atezolizumab in Unresectable Advanced or Metastatic NSCLC in Japan: J-TAIL

EP08.01-005. A Multicenter Prospective Observational Study of Atezolizumab in Unresectable Advanced or Metastatic NSCLC in Japan: J-TAIL

Back to course

Pdf Summary

The J-TAIL study was conducted to evaluate the effectiveness and safety of atezolizumab monotherapy in Japanese patients with unresectable advanced or recurrent non-small cell lung cancer (NSCLC) in a real-world setting. A total of 1,039 patients were enrolled in the study, and the median follow-up was 11.5 months. The study found that atezolizumab demonstrated effectiveness and safety in Japanese patients with previously treated NSCLC. However, caution should be exercised when using atezolizumab in patients with central nervous system metastasis, ECOG performance status 2, and a history of autoimmune disease.<br /><br />The study also identified several factors associated with outcomes in patients treated with atezolizumab, including neutrophil-to-lymphocyte ratio, C-reactive protein levels, and the lung immune prognostic index. The study showed that patients who developed grade 1-2 immune-related adverse events had favorable survival outcomes.<br /><br />The limitations of the study include the absence of a control group, potential errors in measuring progression, and uneven frequency of radiographic examinations across different sites.<br /><br />Overall, the results of the J-TAIL study suggest that atezolizumab is effective and safe for Japanese patients with previously treated NSCLC in a real-world setting. However, further research is needed to determine the optimal use of atezolizumab in specific patient subgroups.

Asset Subtitle

Akito Hata

Meta Tag

Speaker Akito Hata

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

J-TAIL study

atezolizumab

Japanese patients

NSCLC

effectiveness

safety

real-world setting

previously treated

immune-related adverse events

patient subgroups